What should patients verify about insurance coverage for Wegovy in 2026?

In 2026, verify your plan's formulary status for Wegovy, its prior authorization rules, and your out-of-pocket costs under new Medicare Part D caps.

Confirm Wegovy's Formulary Status

An insurance plan's formulary is the official list of prescription drugs it covers. This list is not static; it is updated annually, meaning a drug covered one year may not be covered the next. For 2026, you must obtain and review your plan's formulary as soon as it's released, typically in the fall of 2025, to confirm Wegovy is included.

Formularies are often divided into tiers. Drugs in lower tiers (e.g., Tier 1 for generics) have lower copays, while drugs in higher tiers (e.g., Tier 3 or 4 for brand-name, non-preferred drugs) have higher cost-sharing. Wegovy is typically a higher-tier medication, so its position on the formulary directly impacts your monthly cost.

If Wegovy is not on the formulary, it is considered 'non-covered,' and you would likely be responsible for its full list price. In some cases, your physician can submit a formulary exception request, but approval is not guaranteed. Always check the specific 2026 formulary for your exact health plan.

Understand Prior Authorization and Step Therapy

Most insurance plans require a 'prior authorization' (PA) for expensive medications like Wegovy. This means your physician must submit clinical documentation to the insurer to justify the medical necessity of the prescription before the plan will agree to cover it. This process must be completed and approved before you can fill your prescription.

Common criteria for Wegovy PA approval include having a specific Body Mass Index (BMI) — typically ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity — and sometimes proof of participation in a structured diet and exercise program. Insurers will list their specific 2026 criteria in their policy documents.

Some plans also enforce 'step therapy.' This policy requires you to first try and fail one or more lower-cost alternative medications (like phentermine or contrave) before the plan will approve Wegovy. Check your 2026 plan details to see if step therapy is required for anti-obesity medications.

Medicare Part D Coverage and Cost Caps

A major change impacting 2026 is the Inflation Reduction Act (IRA), which redesigned the Medicare Part D benefit. Beginning in 2025, the law established a $2,000 annual out-of-pocket cap for prescription drugs for Medicare beneficiaries. This cap will be in effect for 2026, significantly limiting costs for those whose plans cover Wegovy.

However, a crucial detail remains: by law, Medicare Part D is generally prohibited from covering medications when prescribed solely for weight loss. This exclusion is part of the original Medicare Modernization Act of 2003. Therefore, coverage for Wegovy under Part D depends on its prescribed purpose.

The pathway for coverage is Wegovy's FDA approval to reduce the risk of major adverse cardiovascular events (MACE) like heart attack and stroke in adults with established cardiovascular disease and either overweight or obesity. Medicare Part D plans may cover Wegovy for this specific, risk-reducing indication. Patients must verify that their Part D plan covers Wegovy for this use in 2026.

Calculate Commercial Plan Cost-Sharing

Your total out-of-pocket cost for Wegovy is more than just the copay. First, you must meet your annual deductible, which is the amount you pay for healthcare services and prescriptions before your insurance begins to contribute. On a high-deductible health plan (HDHP), you might pay the full negotiated price for Wegovy for several months.

After meeting your deductible, you will pay either a copay (a fixed dollar amount, e.g., $50) or coinsurance (a percentage of the drug's cost, e.g., 30%). Expensive specialty drugs like Wegovy often have coinsurance, which can result in a high monthly cost until you reach your plan's out-of-pocket maximum.

To budget for 2026, find your plan's summary of benefits to identify your deductible, your copay/coinsurance for higher-tier drugs, and your annual out-of-pocket maximum. This will help you predict your total potential yearly cost for the medication.

Check for Manufacturer Savings Programs

Novo Nordisk, the manufacturer of Wegovy, typically offers a savings card program to reduce the cost for eligible patients. These programs are designed for individuals with commercial insurance, not those with government-sponsored plans like Medicare or Medicaid.

The Wegovy Savings Card can lower a patient's monthly copay significantly, sometimes to as little as $0 or $25, depending on whether their insurance plan covers the drug. However, these programs have an annual maximum benefit, after which the patient is responsible for their normal copay.

The terms, eligibility, and maximum benefits for these savings programs change each year. You should check the official Wegovy website in late 2025 or early 2026 to see the details of the 2026 savings program and to enroll if you are eligible.

Bottom Line

Navigating insurance for Wegovy in 2026 requires proactive research. Key steps include verifying its placement on your plan's formulary, understanding the prior authorization and step therapy rules, and calculating your total out-of-pocket liability based on your deductible and copay.

For Medicare beneficiaries, the landscape is defined by the $2,000 out-of-pocket cap and the critical need to confirm coverage is provided for Wegovy's cardiovascular risk reduction indication, as coverage for weight loss alone is excluded.

If brand-name access proves to be a financial barrier, physician-supervised [weight loss programs](/weight-loss) can help you and your doctor evaluate all available medical options through licensed U.S. pharmacies. A comprehensive plan considers both clinical needs and financial realities.

This information is for educational purposes only and does not constitute medical advice.

Drafted by the GOAL.MD Authority Engine and approved editorially by GOAL.MD staff. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.